ClinicalTrials.gg
CompletedNCT01983449DANCEUpdated Mar 8, 2018

Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease

A Phase 4 interventional study of Dexamethasone Sodium Phosphate Injection, USP in Peripheral Arterial Diseases, sponsored by Mercator MedSystems, Inc.. Completed at 38 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-08.

Sponsored by Mercator MedSystems, Inc. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
285
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.

Enrollment
48th of 373
285 · median 64
Started
2013
with 25 others
Phase 4
25 of 479
3 open now
Registered
142nd of 479
by date

Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 48th largest by enrollment of the 373 interventional ones that give a count, is one of 26 that started in 2013, is one of 25 in phase 4, and was the 142nd registered.

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 479 studies in Peripheral Arterial Disease with a site in United States, or all of them as a file.
02

Study summary

To assess the safety and effectiveness of adventitial deposition of the Study Drug in reducing inflammation and restenosis in patients with clinical evidence of claudication or critical limb ischemia and an angiographically significant lesion in the superficial femoral and/or popliteal arteries.

Study Drug and Dose: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/ml, with dilute contrast (17%) administered to the adventitia in a dose of 1.6 mg per cm of desired vessel treatment length.

Read the detailed description

This trial will examine the ability for adventitial dexamethasone to safely delay restenosis in patients at least 18 years of age, who have peripheral atherosclerotic lesions involving the superficial femoral and/or popliteal arteries. These patients have no current therapeutic alternatives beyond the procedure used to open, or revascularize, their superficial femoral and/or popliteal arteries. Metal stents have the potential to fracture when implanted in this artery segment due to continual flexion and bending of the knee. It is desirable to improve the patency of this artery after percutaneous transluminal angioplasty (PTA) and/or atherectomy-based revascularization.

03

Conditions studied

  • Peripheral Arterial Diseases

Keywords

  • Adventitia
  • Peripheral Artery Disease
  • Restenosis
  • Inflammation
  • Anti-Inflammatory
  • Dexamethasone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Screening Criteria

    • Male or non-pregnant female ≥18 years of age
    • Rutherford Clinical Category 2-4
    • Clinical diagnosis of PAD requiring revascularization, secondary to atherosclerosis affecting a lower limb
    • Patient is willing to provide and comply with the required follow up visits, testing schedule, and medication regimen
  • Procedural Criteria

    • De novo or nonstented restenotic lesions >90 days from prior angioplasty and/or atherectomy, at least 3 cm from any previously placed stent or vascular surgery site
    • >70% diameter stenosis up to 15 cm in total length (with no greater than 3 cm length of contiguous intervening normal artery) in the superficial femoral and/or popliteal artery (between the profunda and tibioperoneal trunk)
    • Reference vessel diameter ≥3mm and ≤ 8mm
    • Successful wire crossing of lesion
    • A patent artery proximal to the index lesion free from significant stenosis (significant stenosis is defined as >50% in iliac or >30% stenosis in common femoral artery) as confirmed by angiography (treatment of target lesion after successful treatment of iliac or common femoral artery lesions is acceptable)

Exclusion criteria

Exclusion Criteria:

  • Screening Criteria

    • Pregnant, nursing or planning on becoming pregnant in \< 2 years
    • of \<2 years
    • Known active
    • History of solid organ transplantation
    • Patient actively participating in another device or drug study
    • History of hemorrhagic stroke within 3 months
    • Previous or planned surgical or interventional procedure within 30 days of index procedure
    • Chronic renal insufficiency with \<29
    • Prior bypass surgery, stenting of the target lesion
    • Inability to take required study medications
    • or known to dexamethasone sodium phosphate, contrast media, or Physician prescribed antiplatelet regimen as indicated
    • Systemic fungal infection
    • Anticipated use of IIb/IIIa inhibitor prior to index lesion treatment
    • Acute or sub-acute thrombus, acute vessel occlusion or sudden symptom onset
    • Acute limb ischemia
    • Prior participation of the index limb in the current study (contralateral treatment is allowed)
    • Inability to ambulate (e.g. from prior ipsilateral or contralateral amputation)
    • Patient is receiving already, however locally acting inhaled steroids for asthma treatment do not exclude patients from the trial
  • Procedural Criteria

    • Lesions extending into the trifurcation or above the profunda
    • Heavy eccentric or moderate circumferential calcification at index lesion, which in the judgment of the investigator would prevent penetration of the Micro-Infusion Catheter needle through the vessel wall
    • Lesion length is >15 cm as measured from proximal normal vessel to distal normal vessel, or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured
    • Inadequate distal outflow defined as absence of at least one patent tibial artery (no lesion >50% stenosis) with flow into the foot
    • Use of adjunctive therapies other than angioplasty, atherectomy (mechanical or laser) or bare metal stenting (i.e. scoring/cutting balloon, drug-eluting stent, drug-coated balloon, cryoplasty, etc.)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
285 participants (actual)

Study arms

  • Experimental
    Adventitial Dexamethasone

    In patients receiving either angioplasty or atherectomy-based revascularization (pre-stratified to each by 50% of the total study), dexamethasone will be delivered to the adventitia following revascularization.

    Drug: Dexamethasone Sodium Phosphate Injection, USP

Interventions

06

What researchers measure

Primary outcomes

  1. MALE-POD

    Acute safety safety outcomes will be determined by evaluating the type, frequency, severity, and relatedness of Major Adverse Limb Events or Peri-Operative Death (MALE+POD) within 30 days from the procedure for all subjects.

    Time frame: 30 days

  2. Duplex ultrasound index lesion binary restenosis

    Binary restenosis will be judged by core laboratory interpretation with peak systolic velocity ratio (PSVR) greater than 2.4.

    Time frame: 6 months

  3. Duplex ultrasound index lesion binary restenosis

    Binary restenosis will be judged by core laboratory interpretation with peak systolic velocity ratio (PSVR) greater than 2.4.

    Time frame: 12 months

Secondary outcomes

  1. Long term safety

    Long term safety outcomes that occur after 30 days through 6 months post-procedure will be determined by evaluating adverse events.

    Time frame: 30 days to 6 months

  2. Duplex ultrasound index lesion flow limiting restenosis

    Flow limiting restenosis will be judged by core laboratory as PSVR\>4.0.

    Time frame: 6 and 12 months

  3. Change in inflammatory biomarkers

    Change in inflammatory biomarkers will be measured with a panel of biomarkers in 1/3 of patients.

    Time frame: Baseline and 24 hours

  4. Vascular patency

    Target lesion revascularization (TLR) rate, target extremity revascularization (TER) rate, limb salvage rate and primary patency (PSVR≤2.4 and no TLR) at 6, 12, 18 and 24 months. Note: provisional stenting performed during the index procedure shall not be considered to be TLR, TER or loss of primary patency.

    Time frame: 6, 12, 18 and 24 months

  5. Clinical outcome measures

    Modified Walking Impairment Questionnaire, Ankle-Brachial Index, Rutherford Score.

    Time frame: 1, 6, 12, 18 and 24 months

  6. Infusion Technical Success

    Distribution grade around infusion sites.

    Time frame: Intraprocedural

  7. Procedural Success

    Establishment of antegrade flow with residual stenosis of \<30% by angiogram.

    Time frame: Intraprocedural

  8. Healthcare Economics

    Number of return visits and hospitalizations, time from index procedure to required revascularization and number of index-lesion-related readmissions within 30 days will be measured.

    Time frame: 30 days

07

Study locations

38 sites
  • Arizona Heart Hospital / Abrazo Health Care Research / Tenet Health
    Phoenix, Arizona 85016, United States
  • Pima Vascular
    Tucson, Arizona 85718, United States
  • Arkansas Heart Hospital
    Little Rock, Arkansas 72211, United States
  • Cardiovascular Medical Group of Southern California / Cardiovascular Research Foundation
    Beverly Hills, California 90210, United States
  • St. Joseph Hospital of Orange Heart and Vascular Center
    Orange, California 92868, United States
  • San Francisco VA Medical Center
    San Francisco, California 94121, United States
  • University of California San Francisco Medical Center
    San Francisco, California 94131, United States
  • VA Eastern Colorado Healthcare System
    Denver, Colorado 80220, United States
  • Hartford Hospital
    Hartford, Connecticut 06702, United States
  • MedStar Health Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • First Coast Cardiovascular Institute
    Jacksonville, Florida 32216, United States
  • Munroe Regional Medical Center
    Ocala, Florida 34471, United States
  • Coastal Vascular & Interventional
    Pensacola, Florida 32504, United States
  • St. Joseph Hospital
    Fort Wayne, Indiana 46802, United States
  • Willis-Knighton Medical Center
    Shreveport, Louisiana 71103, United States
  • UMass Medical School
    Worcester, Massachusetts 01655, United States
  • St. John Providence Hospital and Medical Center
    Detroit, Michigan 48326, United States
  • Hattiesburg Clinic
    Hattiesburg, Mississippi 39401, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • St.Louis University Hospital
    Saint Louis, Missouri 63110, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03766, United States
  • Deborah Heart & Lung Center
    Browns Mills, New Jersey 08015, United States
  • Hunterdon Medical Center
    Flemington, New Jersey 08822, United States
  • Rutgers New Jersey Medical School
    Newark, New Jersey 07103, United States
  • Albany Vascular Group
    Albany, New York 12208, United States
  • Gotham Cardiovascular Research / New York Cardiovascular Associates
    New York, New York 10001, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • UNC Health Care - Rex Hospital
    Raleigh, North Carolina 27607, United States
  • OhioHealth
    Columbus, Ohio 43214, United States
  • UPMC Heart & Vascular Institute
    Pittsburgh, Pennsylvania 15232, United States
  • The Miriam Hospital
    Providence, Rhode Island 02906, United States
  • Wellmont CVA Heart Institute
    Kingsport, Tennessee 37660, United States
  • DFW Vascular Group
    Dallas, Texas 75208, United States
  • Plaza Medical Center at Fort Worth
    Fort Worth, Texas 76104, United States
  • Palestine Regional Medical Center
    Palestine, Texas 75801, United States
  • Mission Research Institute (Guadalupe Regional Medical Center)
    Seguin, Texas 78155, United States
  • Alpine Research / Utah Cardiology
    Salt Lake City, Utah 84041, United States
  • University of Washington Veterans Center
    Seattle, Washington 98195, United States
08

References and documents

Publications

  • Razavi MK, Donohoe D, D'Agostino RB Jr, Jaff MR, Adams G; DANCE Investigators. Adventitial Drug Delivery of Dexamethasone to Improve Primary Patency in the Treatment of Superficial Femoral and Popliteal Artery Disease: 12-Month Results From the DANCE Clinical Trial. JACC Cardiovasc Interv. 2018 May 28;11(10):921-931. doi: 10.1016/j.jcin.2017.12.015. Epub 2018 May 2. PubMed 29730377 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Dec 2016 and a completion of Jan 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2013
First posted
Nov 14, 2013
Start
Nov 2013
Primary completionActual
Dec 2016
CompletionActual
Jan 2018
Last update
Mar 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01983449
Lead sponsor
Mercator MedSystems, Inc.
Responsible party
Sponsor
First posted
Nov 14, 2013
Start date
Nov 2013
Primary completion
Dec 2016
Completion
Jan 2018
Last update
Mar 8, 2018

Study contacts

Mahmood Razavi, MD
principal investigator · St. Joseph's Vascular Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone phosphate

Start the discussion